個(gè)人簡(jiǎn)介：
2013年畢業(yè)于中國(guó)科學(xué)院上海生命科學(xué)研究院，獲得理學(xué)博士學(xué)位,；2013-2016年在中國(guó)科學(xué)院上海生命科學(xué)研究院從事博士后研究,，并聘任副研究員；2016-2018年在美國(guó)德克薩斯大學(xué)西南醫(yī)學(xué)中心（UT Southwestern Medical Center）病理系和免疫系從事博士后研究,；之后進(jìn)入上海交通大學(xué)醫(yī)學(xué)院公共衛(wèi)生學(xué)院工作,，并破格受聘研究員、博士生導(dǎo)師,。主要從事腫瘤病因,、腫瘤化學(xué)預(yù)防與免疫預(yù)防研究，通過深入研究腫瘤遺傳因素與環(huán)境因素如何調(diào)控癌前病變及腫瘤免疫微環(huán)境,，進(jìn)而影響腫瘤發(fā)生發(fā)展及藥物應(yīng)答,，從中尋找有效的化學(xué)預(yù)防和免疫預(yù)防的靶標(biāo)及天然靶向的植物活性物質(zhì)，系統(tǒng)性地探討和發(fā)展用于腫瘤多階段,、多層次預(yù)防的新技術(shù)和新方法,。近年來，研究成果以第一作者或通訊作者發(fā)表在Nat Genet,、GUT,、Nat Commun、Clin Cancer Res,、Clin Transl Med,、Cell Discovery、EBiomedicine等國(guó)際一流雜志,，共發(fā)表SCI研究論文30余篇,，特約綜述2篇。申請(qǐng)中國(guó)發(fā)明專利8項(xiàng),，授權(quán)4項(xiàng),。作為項(xiàng)目負(fù)責(zé)人主持科技部重大專項(xiàng)子課題（1項(xiàng)）,、國(guó)家自然科學(xué)基金委面上項(xiàng)目（2項(xiàng)）和青年項(xiàng)目（1項(xiàng)）。
學(xué)術(shù)任職：任中國(guó)抗癌協(xié)會(huì)腫瘤病因?qū)W分委會(huì)青年委員,、中國(guó)抗癌協(xié)會(huì)腫瘤代謝分委會(huì)免疫代謝學(xué)組全國(guó)委員,、上海市毒理學(xué)會(huì)理事及《中華疾病控制雜志》青年編委等。
獎(jiǎng)勵(lì)榮譽(yù)：2013年獲上海市優(yōu)秀畢業(yè)生,、2014年獲賽諾菲-中國(guó)科學(xué)院上海生命科學(xué)研究院優(yōu)秀博士后,、2016年獲賽諾菲-中國(guó)科學(xué)院上海生命科學(xué)研究院優(yōu)秀青年人才榮譽(yù)、2019年入選上海交通大學(xué)醫(yī)學(xué)院優(yōu)秀青年人才培育計(jì)劃,、2019年入選上海市浦江人才計(jì)劃,、2019年入選上海市高校青年東方學(xué)者、2019年入選上海市青年拔尖人才計(jì)劃,、2020年入選上海交通大學(xué)醫(yī)學(xué)院九龍醫(yī)學(xué)優(yōu)秀青年人才獎(jiǎng),、2020年入選國(guó)家萬人計(jì)劃青年拔尖人才計(jì)劃、
2021年入選上海市醫(yī)苑新星青年醫(yī)學(xué)人才-公共衛(wèi)生領(lǐng)導(dǎo)者計(jì)劃,。
研究領(lǐng)域：腫瘤病因,、腫瘤化學(xué)預(yù)防和免疫預(yù)防
1、揭示腫瘤遺傳因素與外部環(huán)境因素（如膳食營(yíng)養(yǎng),、情緒壓力,、運(yùn)動(dòng)等健康生活方式）如何調(diào)控癌前病變及腫瘤免疫微環(huán)境進(jìn)而影響腫瘤發(fā)生發(fā)展及藥物應(yīng)答，探索精確靶向腫瘤微環(huán)境的具體途徑,、藥物類型和臨床模式,；
2、發(fā)現(xiàn)腫瘤人群易感標(biāo)志物和診斷治療新靶點(diǎn),，研究靶點(diǎn)功能及其分子調(diào)控和信號(hào)轉(zhuǎn)導(dǎo),，探索天然植物活性成份、化學(xué)小分子藥物等化學(xué)預(yù)防和免疫預(yù)防腫瘤的新機(jī)制和新方法,。
代表性成果：
1. Yang Y, Sun M, Li W, Liu C, Jiang Z, Gu P, Li J, Ba Q*, Li X*, Wang H*. Rebalancing TGF-β/Smad7 signaling via Compound kushen injection in hepatic stellate cells protects against liver fibrosis and hepatocarcinogenesis. Clin Transl Med. 2021 July 4. doi.org/10.1002/ctm2.410
2. Zhou Y#, Li X#, Chen K, Ba Q, Zhang X, Li J, Wang J, Wang H, Liu H. Structural optimization and biological evaluation for novel artemisinin derivatives against liver and ovarian cancers. Eur J Med Chem. 5;211:113000,2021.
3. Li X, Liu Z, Zhang A, Han C, Shen A, Bothman D, Qiao J, Wang Y, Huang X, Fu Y. NQO1-based tumor targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. Nat Commun 10(1):3251,2019.
4. Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X, Wang H. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. GUT 66(1):157-167,2017.
5. Li M#, Zhang Z#, Li X#, Ye J, Wu X, Tan Z, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet 46 (8): 872-6, 2014.
6. Li X, Ba Q, Liu Y, Yue Q, Chen P, Li J, Zhang H, Ying H, Ding Q, Song H, Liu H, Zhang R Wang H. Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein. Cell Discovery. 21;3:17042,2017.
7. Li X, Zhou Y, Liu Y, Zhang X, Chen T, Chen K, Ba Q, Li J, Liu H, Wang H. Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer. EBioMedicine 14:44-54,2016.
8. Li X, Yang X, Liu Y, Gong N, Yao W, Chen P, et al. Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-κB. Clin Cancer Res 1;19(11):2917-28, 2013.
9. Li X, Chen T, Lin S, Zhao J, Chen P, Ba Q, Guo H, Liu Y, Li J, Chu R, Shan L, Zhang W, Wang H. Valeriana jatamansi constituent IVHD-valtrate as a novel therapeutic agent to human ovarian cancer: in vitro and in vivo activities and mechanisms. Curr Cancer Drug Targets 13(4):472-83, 2013.
10. Wang L, Li X, Wang Z, Bancks MP, Carnethon MR, Greenland P, Feng YQ, Wang H, Zhong VW. Trends in Prevalence of Diabetes and Control of Risk Factors in Diabetes Among US Adults, 1999-2018. JAMA.e219883, 2021
11. Chen P, Duan X, Li X, Li J, Ba Q, Wang H. HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α. Oncogene. 39(14):2863-2876,2020.
12. Yang Y, Sun M, Yao W, Wang F, Li X, Wang W, Li J, Gao Z, Qiu L, You R, Yang C, Ba Q, Wang H. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib. J Immunother Cancer. 8(1):e000317,2020.
13. Yao W, Ba Q, Li X, Li H, Zhang S, Yuan Y, Wang F, Duan X, Li J, Zhang W, Wang H.A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer. EBioMedicine.22:58-67,2017.
14. Ba Q, Li X, Huang C, Li J, Fu Y, Chen P, Duan J, Hao M, Zhang Y, Li J, Sun C, Ying H, Song H, Zhang R, Shen Z, Wang H. BCCIPβ modulates the ribosomal and extraribosomal function of S7 through a direct interaction. J Mol Cell Biol 1;9(3):209-219,2017.
15. Chen P, Li B, Zhu Y, Chen W, Liu X, Li M, Duan X, Yi B, Wang J, Liu C, Luo X, Li X, Li J, Liang L, Yin X, Wang H, Jiang X. Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma. Oncotarget. 14;7(24):37319-37330,2016.
16. Chen P, Li C, Li X, Li J, Chu R, and Wang H. Higher dietary folate intake reduces the breast cancer risk: a systematic review and meta-analysis. Brit J Cancer. doi:10.1038/bjc.155 2014.
